Laurel Wealth Advisors (North Carolina)’s GSK GSK Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-757	Closed	-$37.1K	–	376
2025 Q4	$37.1K	Buy	+757	New	+$35.3K	﹤0.01%	358
2025 Q2	–	Sell	-757	Closed	-$29.3K	–	380
2025 Q1	$29.3K	Hold	757	–	–	﹤0.01%	368
2024 Q4	$25.6K	Sell	757 -30	-4%	-$1.08K	﹤0.01%	389
2024 Q3	$32.2K	Buy	787 +423	+116%	+$17.3K	0.01%	359
2024 Q2	$14K	Hold	364	–	–	﹤0.01%	405
2024 Q1	$15.6K	Hold	364	–	–	﹤0.01%	400
2023 Q4	$13.5K	Hold	364	–	–	﹤0.01%	380
2023 Q3	$13.2K	Hold	364	–	–	﹤0.01%	381
2023 Q2	$13K	Hold	364	–	–	﹤0.01%	392
2023 Q1	$13K	Hold	364	–	–	﹤0.01%	392
2022 Q4	$12.8K	Hold	364	–	–	﹤0.01%	369
2022 Q3	$11K	Buy	+364	New	+$13.8K	﹤0.01%	378
2022 Q2	–	Sell	-364	Closed	-$20K	–	656
2022 Q1	$20K	Hold	364	–	–	﹤0.01%	343
2021 Q4	$20K	Hold	364	–	–	﹤0.01%	343
2021 Q3	$17K	Hold	364	–	–	﹤0.01%	357
2021 Q2	$18K	Hold	364	–	–	﹤0.01%	388
2021 Q1	$16K	Hold	364	–	–	﹤0.01%	373
2020 Q4	$17K	Sell	364 -400	-52%	-$18.4K	﹤0.01%	362
2020 Q3	$36K	Hold	764	–	–	0.01%	268
2020 Q2	$39K	Buy	764 +400	+110%	+$20.5K	0.01%	251
2020 Q1	$17K	Hold	364	–	–	0.01%	305
2019 Q4	$21K	Hold	364	–	–	0.01%	319
2019 Q3	$19K	Hold	364	–	–	0.01%	320
2019 Q2	$18K	Hold	364	–	–	0.01%	328
2019 Q1	$19K	Hold	364	–	–	0.01%	312
2018 Q4	$17K	Buy	+364	New	+$17.9K	0.01%	305

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s GSK Position: Q1 2026 in Review

Laurel Wealth Advisors (North Carolina) sold out of GSK (GSK) in Q1 2026, closing a stake of 757 shares — an estimated $37.1K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in GSK in Q4 2018 and held it in 26 quarters. The position peaked at $39K in Q2 2020. 1,035 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Laurel Wealth Advisors (North Carolina) reported no remaining GSK position as of Q1 2026 after selling out during the quarter.
Laurel Wealth Advisors (North Carolina) sold 757 GSK shares in Q1 2026, an estimated $37.1K.
Laurel Wealth Advisors (North Carolina) first reported a position in GSK in Q4 2018 and held it in 26 quarters.
Laurel Wealth Advisors (North Carolina)'s GSK position peaked at $39K in Q2 2020.
1,035 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q1 2026, filed 13 May 2026.